
Staley A. Brod, MD
Professor
Location
- Neurosciences - Froedtert Hospital Clinic
- 900 N. 92nd St.
- Milwaukee, WI 53226
Specialties
- Internal Medicine
- Neurology
Neuroscience Center - Froedtert Hospital Specialty Clinics
In the not so distant past, multiple sclerosis was often a devastating illness in many patients because neurologists did not have effective therapeutic options. The only standard treatment was bedrest during the acute attacks. When I started in my MS fellowship in 1987, there were two medications available - corticosteroids and ACTH. These medications were only effective in treating acute exacerbations or attacks of the disease. Starting in 1993 with the introduction of Betaseron and during the following 23 years 12 additional disease modifying medications were approved for the treatment of relapsing forms of multiple sclerosis. These therapies have had a significant impact on disease progression by decreasing lesion formation in the brain and spinal cord and decreasing acute MS attacks or relapses. In addition new symptomatic therapies have resulted in better control of fatigue, bladder problems, depression and spasticity. In many cases multiple sclerosis has become a manageable problem in many patients. Our biggest challenge at present in the field is treating disease progression in the absence of attacks or exacerbations. With the help of multiple sclerosis patients participating in clinical trials we will discover new agents to overcome the problem of treating disease progression.
Overview
Diseases and Conditions
- Multiple Sclerosis (MS)
- Neuromyelitis Optica (NMO)
- Autoimmune Diseases of the Central Nervous System
- Autoimmune Encephalitis
Treatments and Services
- Neuroimmunology
- Oral/injectable/infused and Symptomatic Therapies for Multiple Sclerosis
- Virtual Visit
Patients Ages Seen
- Adult
Languages
- English
Hospital Affiliations
- Froedtert Hospital – Milwaukee
Board Certifications
- Neurology
- Internal Medicine
Clinic Locations
Neurosciences - Froedtert Hospital Clinic
- 900 N. 92nd St.
- Milwaukee, WI 53226
- (414) 805-5400
- Get Directions

Biography
Staley A. Brod, MD, is a Professor of Neurology at the Medical College of Wisconsin. He graduated from Williams College AB in Philosophy in 1972 and attended medical school in Belgium at the Rijksuniversitair Centrum Antwerpen, the Universitair Instelling Antwerpen and obtained his MD from the Medical College of Ohio in 1981. He completed residencies in Internal Medicine at the Medical College of Ohio and in Neurology at Yale-New Haven Medical Center/Yale Univ Medical School. He is board certified in both Internal Medicine and Neurology. He was a Research and Clinical Fellow in Neurology at the Center for Neurologic Disease, Brigham and Women's Hospital, Harvard Medical School from 1987-1990, an Associate Physician in Neurology at Brigham and Women's Hospital and an Instructor in Neurology (Medicine) at the Harvard Medical School from 1990-1991. Dr. Brod was an Assistant Professor of Neurology in Division of Neuroimmunology, UT Southwestern Med School in Dallas from 1991-93 and subsequently Professor of Neurology in the MS Research Group at the UT Houston until 2015.
Education and Training
Doctor of Medicine - Medical College of Ohio - Toledo, OH (1981)
Resident in Medicine - Medical College of Ohio - Toledo, OH (1982-1984)
Assistant Resident in Neurology - Yale-New Haven Hospital - New Haven, CT (1984-1986)
Chief Resident in Neurology - Yale-New Haven Hospital - New Haven, CT (1986-1987)
Research & Clinical Fellow in Neurology - Brigham and Women's Hospital, Harvard Medical School - Boston, MA (1987-1990)
Publications
-
Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects.
(Brod SA.) Mult Scler Relat Disord. 2020 Nov;46:102538 PMID: 33059216 PMCID: PMC7539063 SCOPUS ID: 2-s2.0-85092416377 10/16/2020
-
In MS: Immunosuppression is passé.
(Brod SA.) Mult Scler Relat Disord. 2020 May;40:101967 PMID: 32007655 SCOPUS ID: 2-s2.0-85078735778 02/03/2020
-
Ingested ACTH blocks Th17 production by inhibiting GALT IL-6.
(Dittel LJ, Dittel BN, Brod SA.) J Neurol Sci. 2020 Feb 15;409:116602 PMID: 31812846 SCOPUS ID: 2-s2.0-85075869362 12/10/2019
-
Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects
(Brod SA.) Multiple Sclerosis and Related Disorders. November 2020;46 SCOPUS ID: 2-s2.0-85092416377 11/01/2020
-
Plegia to walking: AHSCBMT in severe NMOSD relapse
(Nicola Carlisle,1 Parameswaran Hari,2 Staley Brod.) BMJ Neurology Open. BMJ Neurology Open 2020;2:e000073. doi:10.1136/ bmjno-2020-000073 10/26/2020
-
(Freedman MS, Brod S, Singer BA, Cohen BA, Hayward B, Dangond F, Coyle PK.) J Neurol. 2020 Jan;267(1):64-75 PMID: 31559532 PMCID: PMC6954891 SCOPUS ID: 2-s2.0-85074028696 09/29/2019
-
Tumefactive demyelination: Clinical outcomes, lesion evolution and treatments.
(Brod SA, Lindsey JW, Nelson F.) Mult Scler J Exp Transl Clin. 2019 Apr-Jun;5(2):2055217319855755 PMID: 31245023 PMCID: PMC6582300 06/28/2019
-
Myelinating Proteins in MS Are Linked to Volumetric Brain MRI Changes.
(Brod SA, Lincoln JA, Nelson F.) J Neuroimaging. 2019 05;29(3):400-405 PMID: 30748043 SCOPUS ID: 2-s2.0-85061374097 02/13/2019
-
Ingested (oral) rituximab inhibits EAE.
(Brod SA.) Cytokine. 2016 09;85:177-83 PMID: 27372916 SCOPUS ID: 2-s2.0-85039561776 07/04/2016
-
Ingested (oral) anti-IL-12/23 inhibits EAE.
(Brod SA.) J Neurol Sci. 2016 Feb 15;361:19-25 PMID: 26810510 SCOPUS ID: 2-s2.0-84958957357 01/27/2016
-
Ingested (oral) tocilizumab inhibits EAE.
(Brod SA, Bauer VL.) Cytokine. 2014 Aug;68(2):86-93 PMID: 24845797 SCOPUS ID: 2-s2.0-84899838838 05/23/2014
-
(Freedman, M. S.rnBrod, S.rnSinger, B. A.rnCohen, B. A.rnHayward, B.rnDangond, F.rnCoyle, P. K..) J Neurol. 10.1007/s00415-019-09532-5 09/29/2019